NASDAQ: BIVI · Life Sciences · 4 alerts · CIK 1580149
Share price
$1.08Close, Nov 16
Market cap
$11.6M
Shares outstanding
10.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biovie Inc. filings on SEC EDGAR ↗
BioVie Inc. held its 2026 Annual Meeting of Stockholders where shareholders elected six directors to the board and ratified EisnerAmper LLP as the independent auditor for fiscal 2027. Shareholders also approved an amendment to the 2019 Omnibus Equity Incentive Plan, significantly increasing the share pool from 399,509 to 3,100,000 shares.
BioVie Inc. reported a net loss of $5.6 million for the quarter ended September 30, 2026, compared to a $5.1 million loss in the prior year period. The company remains in the clinical stage with no revenue, focusing its spending on research and development for neurodegenerative and liver disease therapies.
BioVie Inc. entered into a securities purchase agreement with an institutional investor for a $4.74 million registered direct offering and concurrent private placement. The company issued 960,000 shares and 2,002,500 pre-funded warrants at $1.60 per share/equivalent, along with 2,962,500 common warrants. Proceeds are intended for working capital and general corporate purposes.